Boston Scientific Delivers Q2 Sales Growth Across Its Product Lines
Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.
You may also be interested in...
Boston Scientific is looking ahead to the next-generation Acurate neo2 valve after results of SCOPE I showed worse rates of kidney injury and severe aortic regurgitation in patients treated with the self-expanding Acurate neo valve than in patients treated with Edwards’ Sapien 3 valve.
Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.
Despite Paclitaxel Warnings, Physicians Endorse Boston Sci’s Eluvia Stent For NTAP In CMS Pay Proposal Comments
Cardiologists and radiologists spoke in support of new technology add-on payments for Boston Scientific’s Eluvia drug-eluting stent, used to treat patients with peripheral artery disease, in comments on the US Medicare agency's Inpatient Prospective Payment System (IPPS) rule for 2020, despite concerns about paclitaxel-coated stents discussed at a late June US FDA Advisory Committee meeting.